{"organizations": [], "uuid": "b2934bb69f00a662edee2c379e9de586693e30fa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abeona-receives-fda-rare-pediatric/brief-abeona-receives-fda-rare-pediatric-disease-designation-for-abo-202-gene-therapy-program-in-cln1-disease-idUSFWN1QX0PZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-15T14:53:00.000+02:00", "replies_count": 0, "uuid": "b2934bb69f00a662edee2c379e9de586693e30fa"}, "author": "", "url": "https://www.reuters.com/article/brief-abeona-receives-fda-rare-pediatric/brief-abeona-receives-fda-rare-pediatric-disease-designation-for-abo-202-gene-therapy-program-in-cln1-disease-idUSFWN1QX0PZ", "ord_in_thread": 0, "title": "BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "gene therapy program in cln1 disease reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "abeona therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 15, 2018 / 12:56 PM / Updated 15 minutes ago BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease Reuters Staff 1 Min Read March 15 (Reuters) - Abeona Therapeutics Inc: * ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE * ABEONA THERAPEUTICS - FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 PROGRAM, AN AAV-BASED GENE THERAPY FOR TREATMENT OF CLN1 DISEASE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-15T14:53:00.000+02:00", "crawled": "2018-03-15T15:24:00.012+02:00", "highlightTitle": ""}